Market Research Logo

Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets

Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets

The global gastric cancer diagnostic/screening and treatment market was $235.5 billion in 2014. This market is expected to grow from $241.7 billion in 2015 to nearly $318.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.7%.

This report provides:

An overview of the global markets for gastric cancer testing, treatment and prevention.

Analyses of market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.

Detailed information pertaining to the clinical manifestations, diagnosis, and staging of early gastric cancer.

Analysis of recent and projected technological trends for treatment and diagnosis.

Assessment of the market's pipeline broken down by phase of development.

Information on licensing agreements as well as research and development partnerships and agreements.

Comprehensive company profiles of major players in the field.


SCOPE AND FORMAT

This report will give an overall update on gastric cancer. It will review global markets for biologic therapeutics for gastric cancer and will forecast trends for use of diagnostics, screening and cancer treatment through 2020. It will cover important therapies, biologics, diagnostics, market share, products on the market and market share by company and statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market. Current issues and trends affecting the industry, costs and factors influencing demand will be discussed. The report covers diagnostics, therapeutics, biological products in development, biological products in clinical trials, and currently marketed and late-stage developments in biologic cancer products. In addition, this report includes:

Treatment trends and sales patterns across major cancer indications with market performance of major pharmaceutical companies.

Forecast sales of leading products across major indications to 2020.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE AND FORMAT
INTENDED AUDIENCE
METHODOLOGY
RELATED BCC RESEARCH REPORTS
ANALYST'S CREDENTIALS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ MILLIONS)
CHAPTER 3 CANCER
WHAT IS CANCER?
CAUSES OF CANCER GROWTH
CANCER TREATMENT STRATEGIES
COMMON TREATMENTS AND PROBLEMS
Surgery
Chemotherapy
Radiation Treatment
Hormone Therapy
Targeted Therapy
GASTRIC CANCER
CHAPTER 4 INTRODUCTION TO GASTRIC CANCER
TABLE 1 MAIN CATEGORIES OF CANCER
DIGESTIVE SYSTEM AND CANCER
ESOPHAGEAL CANCER
GASTRIC CANCER GLOBAL INCIDENCE
SUBTYPES AND CHARACTERISTICS
SMALL INTESTINE CANCER
STOMACH CANCER/GASTRIC CANCER OVERVIEW
TABLE 2 TYPES OF STOMACH CANCER
TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER
TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER
CAUSES
TABLE 5 RISK FACTORS
TABLE 6 CAUSES OF GASTRIC CANCER
SYMPTOMS
TABLE 7 SYMPTOMS
THERAPEUTIC OPTIONS
RELATED CANCERS AND OVERVIEW
KIDNEY CANCER
TARGETED THERAPIES FOR KIDNEY CANCER
TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER
SORAFENIB (NEXAVAR)
SUNITINIB (SUTENT)
TEMSIROLIMUS (TORISEL)
EVEROLIMUS (AFINITOR)
BEVACIZUMAB (AVASTIN)
PAZOPANIB (VOTRIENT)
AXITINIB (INLYTA)
LIVER
PANCREATIC CANCER
SUMMARY
CHAPTER 5 GASTRIC CANCER SCREENING, DIAGNOSIS AND MARKET
SCREENING
SCREENING METHODS
TABLE 9 GASTRIC SCREENING METHODS
SCREENING AND BENEFITS
SCREENING MODALITIES
Barium-Meal Gastric Photofluorography
Gastric Endoscopy
Serum Pepsinogen
GASTRIC SCREENING IN UNITED STATES
GASTRIC CANCER SCREENING WORLDWIDE
Conclusions
CHAPTER 6 GASTRIC SCREENING AND DIAGNOSIS MARKET
TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)
SCREENING
TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ MILLIONS)
DIAGNOSIS AND PROGNOSIS
TESTS
TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER
IMAGING TESTS
Upper Gastrointestinal (GI) Series
Computed Tomography (CT or CAT) Scan
Magnetic Resonance Imaging (MRI) Scan
Positron Emission Tomography (PET) Scan
Chest X-Ray
Laparoscopy
Helicobacer Pylori
TABLE 13 TESTS USED TO DETECT H. PYLORI
Lab Tests
Costs
TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)
SERUM PEPSINOGEN PREDICTS GASTRIC ADENOCARCINOMA
CHAPTER 7 GASTRIC CANCER TREATMENT OPTIONS
CURRENT PRACTICES
TABLE 15 TYPES OF STANDARD TREATMENT
CHEMOPREVENTION
ANTIOXIDANTS
ANTIBIOTICS
Non-Steroidal Anti-Inflammatory Drugs (Including Aspirin)
STAGING
Sentinel Lymph Node Mapping
Surgery
Chemotherapy
Radiation Therapy
Chemoradiation
TARGETED THERAPY
Drugs Approved for Stomach (Gastric) Cancer
TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER
PROGNOSIS
PREVENTION
CHEMOTHERAPY DRUGS AND COMBINATIONS
TARGETED THERAPY OVERVIEW
Pembrolizumab
Ramucirumab
Afinitor (Everolimus)
Apatinib
FAILED DRUGS
Cetuximab
Tykerb (Lapatinib)
Expected Treatment Outcomes
GASTROINTESTINAL CANCER: MONOCLONAL ANTIBODIES
TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED
ANTIBODY THERAPEUTICS
TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER
TREATMENT
TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT
AVASTIN (BEVACIZUMAB)
HERCEPTIN (TRASTUZUMAB)
VECTIBIX (PANITUMUMAB)
CHAPTER 8 MARKET DYNAMICS AND OVERVIEW
TABLE 21 CANCER KEY FACTS
STANDARD TREATMENTS
GLOBAL CANCER MARKET TRENDS
TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)
FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)
TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)
FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)
TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015
GLOBAL ONCOLOGY MARKET
TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ MILLIONS)
CANCER DRUGS: PAST PERFORMANCE
TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%)
EMERGING MARKETS
TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ MILLIONS)
FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS)
GASTRIC CANCER TREATMENT COSTS
Drugs Approved for Stomach (Gastric) Cancer
TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS)
TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT
TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ MILLIONS)
FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ MILLIONS)
TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
DRUGS IN DEVELOPMENT
MAJOR PLAYERS
Roche
TABLE 33 PATENT EXPIRIES
Merck/Bristol-Myers Squibb
ISSUES AND TRENDS AFFECTING MARKET
SUMMARY
CHAPTER 9 GASTRIC CANCER TREATMENT AND PREVENTION MARKET
SIZE AND GROWTH
MARKET BY PRODUCT TYPE
CYRAMZA
Kadcyla (ado-trastuzumab emtansine)
Perjeta
Herceptin
ONCOLOGY MARKET AND GROWTH
Leading Drugs
TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS)
MARKET BY GEOGRAPHICAL SEGMENTS
TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)
ONCOLOGY PIPELINE
U.S. Market
JAPAN (ASIA) MARKET
TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
EUROPE MARKET
TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
ASIA MARKET
AUSTRALIA MARKET
SOUTH KOREA MARKET
CHINA MARKET
Gastric Cancer Market in China
TAIWAN MARKET
SINGAPORE MARKET
INDIA MARKET
BIOMAb-EGFR
TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY
CHAPTER 10 PIPELINE, PATENTS AND NEW DEVELOPMENTS
RECENT DEVELOPMENTS AND APPROVALS
TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014
NEW DRUGS/COMPANIES IN DEVELOPMENT
CLINICAL TRIALS IN ONCOLOGY
TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009
FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009
Two New Clinical Trials for Advanced Gastric Cancer
TABLE 43 ROCHE - CLINICAL TRIALS
AZD4547
Pacific Edge
Oncolytics
CHAPTER 11 GLOBAL CANCER STATISTICS
CANCER TRENDS
TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)
TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)
TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)
TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012
TRENDS OVER TIME
FUTURE TRENDS 2020
TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)
CANCER CURE AND COSTS
CAUSES OF RISE IN CANCER CASES
TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
PROJECTIONS TO 2030
TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
CURRENT CANCER TRENDS AND ECONOMIC BURDEN
The Burden of Cancer
EMERGING MARKETS
TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)
TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)
CANCER PREVALENCE AND MARKET
GASTRIC CANCER
TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012
(THOUSANDS)
TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER
AFRICA
ASIA
Cancer Prevention and Screening in Asia
CHINA AND JAPAN
Gastric H. pylori infection
Japan
China
MALAYSIA
INDIA
EUROPE
THE AMERICAS
TABLE 55 AMERICAS: CANCER FACTS
NORTH AMERICA
TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014
TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014
Canada
New Cases of Cancer in 2013
TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)
SUMMARY
CHAPTER 12 COMPANIES AND GLOBAL PLAYERS
COMPANIES
TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS)
CANCER MARKET DYNAMICS
SELECTED COMPANIES AND PROFILES
BIOGEN IDEC
BRISTOL MYERS SQUIBB
ELI LILLY AND COMPANY
GLAXOSMITHKLINE
GENENTECH, INC
Hoffmann-LA Roche INC.
IMMUNOGEN
MERCK & COMPANY
NOVARTIS
PFIZER
ROCHE/GENENTECH
ONCOLYTICS
PACIFIC EDGE DIAGNOSTICS NZ
ZOVA BIOTHERAPEUTICS INC.
CHAPTER 13 PARTNERS IN DEVELOPMENT
RESEARCH AND DEVELOPMENT PARTNERSHIP AGREEMENTS AND TECHNOLOGY AND DIAGNOSTIC AGREEMENTS
CHAPTER 14 REFERENCES

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report